Latest News

Latest News2018-07-31T19:14:53+01:00

OncoAssure launches next-generation prostate test in the US

May 23rd, 2025|

NovaUCD-based medtech OncoAssure has announced the launch of its OncoAssure Prostate Test in the US market, as well as plans to hold an investment round last year. The next-generation prognostic test is designed to support clinical decision-making for men diagnosed with localised prostate cancer, and helps to assess the risk of aggressive disease and disease recurrence. Read More

Cinclus Pharma Partners with Zentiva to Commercialize Linaprazan Glurate in Europe

May 23rd, 2025|

Cinclus Pharma Holding, a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of gastric acid-related diseases, has announced an agreement with Zentiva, a European pharmaceutical company, for the commercialisation and manufacturing of its lead asset, linaprazan glurate, in Europe. Read More

Signum Surgical is pleased to announce the appointment of Ms. Carol Burns as Chief Executive Officer.

April 4th, 2025|

Signum Surgical, the medical technology company developing innovative solutions to treat colorectal diseases, is pleased to announce the appointment of Ms. Carol Burns as Chief Executive Officer. Ms. Burns’ appointment is a pivotal milestone for Signum, as the Company initiates commercialization of BioHealx, a first-of-its-kind medical device for the treatment of anal fistula, a painful and debilitating colorectal condition that affects one in 5,000 people worldwide. Read More [...]

Aruna’s Co-Founder and Chief Scientific Officer, Dr. Steven Stice, Inducted into the 2025 Class of the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows.

April 4th, 2025|

Aruna Bio, Inc., a leader in neural exosome-based therapeutics for the treatment of neurodegenerative conditions, today announced that the Company’s Co-Founder and Chief Scientific Officer, Dr. Steven Stice, has been inducted into the 2025 Class of the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows. Read More

Sigrid Therapeutics (Sigrid) is excited to announce that it has secured U.S. market access for its proprietary SiPore® technology.

March 19th, 2025|

Sigrid Therapeutics (Sigrid) is excited to announce that it has secured U.S. market access for its proprietary SiPore® technology, following the success of the SHINE study, the largest of its kind in prediabetes. The study demonstrated that Carb Fence™, an medical-grade, fast-acting liquid formula powered by SiPore®, effectively reduces long-term blood sugar levels HbA1c (A1C), improves glucose metabolism, and reduces body weight - while preserving muscle mass. These robust [...]

Dublin-based Bounce Insights raises €4.2 million to expand its AI-powered market research platform into the US

December 12th, 2024|

Bounce Insights, an Irish startup specialising in AI-powered market research, has announced a €4.2 million funding round. This funding will fuel the company’s expansion into the US market, including the opening of a New York office to support its 25-person team and plans to triple its headcount globally by the end of 2026. Read more

AnaBio and Milky Mist India announce the launch of the first long-life dairy drink fortified with Anabio encapsulated probiotics.

December 12th, 2024|

South Indian dairy company MilkyMist has teamed up with SIG and AnaBio Technologies to introduce what is claimed to be the world’s first long-life probiotic buttermilk in aseptic carton packs. The ground-breaking development, showcased at Gulfood Manufacturing 2024 in Dubai, represents a major breakthrough in the beverage industry, allowing probiotics to be incorporated into shelf-stable drinks in aseptic cartons for the first time. Read Article Here [...]

First marketing approval in China for Cinclus Pharma

December 12th, 2024|

Swedish clinical-stage drug developer Cinclus Pharma (STO: CINPHA), a specialist in treatments for gastric acid-related diseases, had picked up Chinese approval for linaprazan glurate. The outcome represents the firm’s first marketing approval in China. The approval by the National Medical Products Administration (NMPA) paves the way for commercialization in the People’s Republic of China in 2025. Read Article Here

If you are interested in becoming an Investor or seeking investment, then please contact us.

Go to Top